ANALIZE MEDICALE DE LABORATOR
Aici gasiti analizele medicale grupate pe categorii precum si detalii generale si specifice pentru categoriile respective.
Selectati o categorie din lista de mai jos:
Solutie antistress!
Construieste poduri :)
Prinde pisica neagra :)
SRI International Begins NIAID-Funded Drug Evaluation Program For Tuberculosis
SRI International, an
independent nonprofit research and development organization, announced the initiation of a tuberculosis (TB) preclinical drug
evaluation program in partnership with the National Institute of
Allergy and Infectious Diseases (NIAID), a component of the National
Institutes of Health (NIH). The new program is part of the $56.9
million contract NIAID first awarded to SRI in 2006 to provide
preclinical services for the development of drugs and antibodies as
anti-infective therapeutics.
Among other preclinical TB drug development resources SRI also has
the capability to test up to 30,000 compounds per year against
Mycobacterium tuberculosis (Mtb) strains. Preclinical drug candidates
will be provided by TB researchers via a Non-Clinical Evaluation
Agreement with the NIAID. The findings will be used to guide the
development of new medicines against Mtb, including multi-drug
resistant (MDR) strains prevalent in many parts of the world. NIAID,
by way of its portfolio of drug development contracts, will assist
investigators in moving promising compounds through preclinical
evaluations, including efficacy testing in animal models,
pharmacokinetic analysis and toxicology studies.
"Innovative approaches to TB treatment are needed now, as new TB
cases increase and Mtb bacteria become increasingly drug-resistant,"
said Kristien Mortelmans, Ph.D., Director of the Microbiology Program
within SRI's Biosciences Division and Program Leader. "This project
and our partnership with NIAID will help us find new cures to save
lives and further SRI's mission to help solve important global health
problems."
TB, a contagious infectious bacterial disease, is a global health
threat. According to the World Health Organization (WHO), one third of
the world's population has been infected by the TB bacterium. In
2005, TB caused 1.6 million deaths. Strains that are resistant to a
single drug are found in every country surveyed by the WHO, and
strains resistant to all major anti-TB drugs continue to emerge,
including extensively drug resistant TB (XDR-TB) that now exists in
49 countries.
As part of SRI's strategic expansion of its TB research program, Dr.
Sidharth Chopra recently joined SRI's Microbiology Program, having
recently completed a Fellowship at Stanford University, conducting
research on antitubercular drug discovery. Dr. Chopra will help
accelerate SRI's antitubercular research program.
Under the 2006 contract, Services for the Preclinical Development of
Therapeutic Agents, SRI has been funded to provide five years of
support for the preclinical development of treatments for TB and other
infectious diseases such as avian flu, SARS, West Nile virus,
hepatitis and biodefense pathogens and toxins. SRI has the capability
to perform medicinal chemistry, custom drug synthesis, formulation,
analytical chemistry, clinical manufacturing, microbiology and
virology screening, pharmacokinetics, and safety testing.
More information on the Services for Preclinical Development of
Therapeutic Agents resource and how to access can be found at
http://www3.niaid.nih.gov/research/resources/dmid/pretheraagents. To
access the TB drug screening program, contact Dr. Robert Goldman,
Program Officer, Respiratory Diseases Branch/DMID/NIAID
(rgoldman@niaid.nih.gov).
About SRI International
Silicon Valley-based SRI International is one of the
world's leading independent research and technology development
organizations. SRI, which was founded by Stanford University as
Stanford Research Institute in 1946 and became independent in 1970,
has been meeting the strategic needs of clients and partners for more
than 60 years. Perhaps best known for its invention of the computer
mouse and interactive computing, SRI has also been responsible for
major advances in networking and communications, robotics, drug
discovery and development, advanced materials, atmospheric research,
education research, economic development, national security, and
more. The nonprofit institute performs client-sponsored research and
development for government agencies, businesses, and foundations. SRI
also licenses its technologies, forms strategic alliances, and creates
spin-off companies. In 2007, SRI's consolidated revenues, including
its wholly owned for-profit subsidiary, Sarnoff Corporation, were
approximately $450 million.
SRI International
SRI International Începe NIAID-Finanþat de droguri Evaluarea Programului pentru tuberculozã - SRI International Begins NIAID-Funded Drug Evaluation Program For Tuberculosis - articole medicale engleza - startsanatate